Venofer denied for failing step therapy by Cigna?

Cigna's specific coverage criteria for venofer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applies Step Therapy to Venofer (Iron Sucrose)

Venofer is an intravenous iron formulation. Cigna's step-therapy policy for IV iron typically requires documented trial and failure of — or a clinical reason to bypass — oral iron supplementation before IV iron will be authorized. The denial reflects that Cigna's records do not yet show a completed oral iron step, even if your clinician determined IV iron was appropriate from the outset.

## Why This Is Appealable

Step-therapy protocols are presumptive, not absolute. Federal and most state step-therapy override laws require insurers to grant an exception when: (a) the required first-step drug is contraindicated or clinically inappropriate for the patient; (b) the patient already tried and failed the required step; or (c) the required step would cause clinically significant delay in treatment of a serious condition. Iron-deficiency anemia in the context of chronic kidney disease, active gastrointestinal blood loss, malabsorption, or dialysis frequently meets one or more of these override criteria.

## Federal Appeal Framework

• Internal appeal: File under ACA/ERISA §503. The denial notice must state the specific step-therapy requirement you need to satisfy or override.
• Step-therapy exception request: Many states require a decision on a step-therapy exception within 72 hours (expedited) or a short standard window. Check your state's step-therapy law; Cigna must comply with whichever is more protective.
• External review (ACA §2719): If the internal appeal and exception request both fail, escalate to independent external review within approximately four months of the final denial. External reviewers apply clinical standards, not Cigna's internal formulary hierarchy.

## Documentation to Gather

1. Diagnosis and severity: Confirmed iron-deficiency anemia diagnosis with current lab values (iron studies, hemoglobin) showing clinical severity. 2. Oral iron trial history: If oral iron was tried — dates, product, dose range, duration, and outcome (inadequate response or intolerance with specific symptoms). 3. Clinical reason to bypass oral iron: If oral iron was never tried because it is contraindicated or inappropriate (e.g., active GI bleed, severe malabsorption, dialysis-related iron loss), your prescriber must document that specific clinical rationale. 4. Urgency documentation: Evidence that delay to complete an oral iron trial would worsen the patient's condition (e.g., symptomatic anemia requiring prompt correction before surgery or procedure). 5. Prescriber medical-necessity letter: Should address each step-therapy override criterion Cigna's policy recognizes, citing the FDA-approved Venofer prescribing label and the relevant professional society guideline for the underlying condition.

## Criteria-Mapping Structure for Your Appeal Letter

Identify each step required by Cigna's current Venofer coverage policy, then document your override basis for each:

| Step-Therapy Requirement | Override Basis / Chart Evidence | |---|---| | Trial of oral iron product | Dates, product, outcomes — or documented contraindication | | Minimum duration of oral iron trial | Duration completed — or clinical reason it was not safe to continue | | Prescriber attestation of clinical appropriateness of IV iron | Letter from treating physician with rationale | | Condition consistent with covered IV iron indication | ICD-10 code and confirming clinical notes |

A letter that maps each override criterion to a specific chart fact is far more persuasive than a narrative-only submission.